Articles
NANS, Medical Societies Urge Elevance Health to Reconsider PNS Coverage
The North American Neuromodulation Society (NANS), alongside several leading medical societies, recently submitted a joint…
NANS Applauds Aetna for Revising Policy on Peripheral Electrical Nerve Stimulation for Pain Policy
The North American Neuromodulation Society (NANS) recognizes Aetna for updating its clinical policy on peripheral electrical nerve stimulation (PNS) for pain, expanding access to non-pharmacological treatment options for patients with chronic pain.
NANS Opens Public Comment on Draft PNS Guideline
The North American Neuromodulation Society (NANS) has opened the public comment period for its draft Clinical Guideline on Implantable Peripheral Nerve Stimulation (PNS) for Chronic Pain—one of the first formal guideline initiatives undertaken by the Society.
NANS Joins Multi-Society Effort on PNS Coverage
The North American Neuromodulation Society (NANS) joined several leading medical specialty societies in submitting joint letters to Cigna Healthcare and UnitedHealthcare regarding policies that classify peripheral nerve stimulation (PNS) as investigational for the treatment of chronic pain.
NANS Continues Coverage Advocacy on PNS
As part of its ongoing efforts to protect patient access to evidence-based therapies, NANS has submitted a formal comment letter to Cigna regarding Medical Coverage Policy 0539, which currently classifies Peripheral Nerve Stimulation (PNS) as “not medically necessary.”
NANS Urges Coverage for Peripheral Nerve Stimulation in Chronic Pain
The North American Neuromodulation Society (NANS) has joined seven national medical specialty societies in signing a joint letter urging Blue Cross Blue Shield of Illinois, Montana, New Mexico, Oklahoma, and Texas—as well as the Health Care Services Corporation—to revise their draft policy on implantable peripheral nerve stimulation (PNS) for chronic pain.
NANS and Medical Societies Urge Aetna to Remove Barriers to PNS Access
NANS, joined by 11 leading medical societies, has sent a letter to Aetna urging the insurer to align its Medicare Advantage coverage policies for Peripheral Nerve Stimulation (PNS) with the existing National Coverage Determination (NCD 160.7).
NANS Urges Humana to End Barriers to Peripheral Nerve Stimulation Access
NANS spearheaded a letter to Humana executives after members expressed serious concerns regarding ongoing prior authorization delays and denials for Peripheral Nerve Stimulation (PNS) treatments for Humana Medicare Advantage beneficiaries.
NANS Leads Response Objecting to Cigna’s Depiction of PNS
In March, NANS learned about Cigna’s Medical Coverage Policy characterizing peripheral nerve stimulation (PNS) to treat chronic pain as “not medically necessary.” NANS led the response objecting to Cigna’s depiction of the treatment as lacking medical necessity.
Humana Revises Medicare Advantage Policy Allowing PNS Treatment for Chronic Pain Under Certain Criteria
Humana revised its Medicare Advantage policy regarding coverage of PNS for chronic pain after NANS issued a statement on behalf of 12 medical societies through the Multisociety Pain Workgroup.
NANS leads response to Humana’s new policy that excludes coverage of PNS
In January 2024, Humana issued Medicare Advantage policy HUM-1140-000, excluding from coverage peripheral nerve stimulators (PNS) for treating chronic pain. NANS issued a statement on behalf of 12 medical societies objecting to the policy.